Do We Really Need a Date Rape Drug Marketed for Fibromyalgia?
Xyrem -- Jazz Pharmaceuticals Inc.’s narcolepsy drug -- is safe and effective, said FDA, which is weighing whether to approve the drug for treating...
Cymbalta: A Sweet ROI for Chronic Pain Indication
One new indication for pain = $500 Million in additional sales!
Once a drug is developed for a single indication, gaining approval for additional indications...
Are Pharma Marketers Using Viral Social Media Techniques to Promote Products?
Subtitle: This Bayer Sexy Youtube Video is Popular, but Will It Help Levitra Sales?
Is viral, peer-to-peer pharma marketing an effective tactic? Jeff Chester, who...
Is Phil Mickelson Shilling for Enbrel?
The golf world was stunned by Tiger Woods' recent poor performance. Another bit of "stunning" news hit the golf world yesterday when the #2...
Steve Woodruff, Pharma’s Connection Agent
Steve Woodruff, President of Impactiviti, joins John Mack (@pharmaguy) to discuss his mission as a 'Connection Agent,' connecting people and businesses.
Is FDA Playing “Bait & Switch” with Pharma Marketers?
Sensing that there are a lot of pharma marketers out there who are "angry as hell and don't want to take it any more,"...
Update on FDA Regulation of Pharma Metadata & Impact on Search
Since writing about FDA's letter to Novartis regarding the content of a Facebook Search Button -- see "Implications of FDA’s Warning Letter to Novartis...
Medium vs. Message vs. FDA
Dedicated to the Twitter "debate" about which comes first for the FDA: The Medium or the Message?
"It's the message NOT the medium! This content...
Who’s in Charge of Your “Invisible” Metadata? WARNING: Don’t Invoke the “Invisibility Rule”
My Twitter pals are all atwitter over FDA's recent letter to Novartis citing violative content in a Facebook "Share Widget" that Novartis created (see...
Implications of FDA’s Warning Letter to Novartis Regarding Facebook Share Widget
You know you are getting old when the FDA knows more about Facebook than you do! In a July 29, 2010 letter to Novartis,...
